Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5795571 | 0.78 | TAAR1 (0.36) | ALDH1A1TSHR | |
| SCHEMBL5792353 | 0.77 | TSHR (0.50) | IKBKBSLC2A1CSNK1EKDM4EALDH1A1 | |
| SCHEMBL11098226 | 0.75 | FFAR1 (0.42) | KDM4EALDH1A1SIGMAR1TSHR | |
| SCHEMBL1537231 | 0.75 | CYP1A2 (0.43) | IKBKBSLC2A1CSNK1EKDM4EALDH1A1 | |
| SCHEMBL26999631 | 0.75 | ESR1 (0.41) | IKBKBSLC2A1CSNK1ECA2 | |
| SCHEMBL30125051 | 0.74 | TSHR (0.38) | ALDH1A1TSHR | |
| SCHEMBL1552804 | 0.74 | TSHR (0.38) | ALDH1A1TSHR | |
| SCHEMBL1728815 | 0.74 | IDO1 (0.39) | IKBKBSLC2A1CSNK1ECFDALDH1A1 | |
| SCHEMBL1727508 | 0.74 | IDO1 (0.39) | IKBKBSLC2A1CSNK1ECFDALDH1A1 | |
| SCHEMBL3733185 | 0.72 | TSHR (0.32) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902725-B2 | Heterocyclic derivatives as RORgamma modulators | GENFIT (FR) | 2018-02-27 | — | — | US | disclosed |
| US-20170349582-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2017-12-07 | — | — | US | disclosed |
| EP-3237396-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | Genfit (FR) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016102633-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2016-06-30 | — | — | WO | disclosed |
| US-20060079696-A1 | Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses | GENFIT (FR) | 2006-04-13 | — | — | US | disclosed |
| WO-2006035157-A2 | SUBSTITUTED N-(BENZYL)PHENYLACETAMIDE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME AS PPAR LIGANDS IN THE TREATMENT OF LIPID AND/OR GLUCIDIC DISORDERS | GENFIT (FR) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349582-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | RORC, RORB, RORA | IKBKB 194/4885SLC2A1 4856/4885CSNK1E 214/4885 |
| US-20060079696-A1 | Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses | AADAC, NAT1, PARN | IKBKB 835/4885SLC2A1 2661/4885CSNK1E 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.